Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.
Children diagnosed with cancer are now living longer as a result of advances in treatment. However, some commonly used anticancer drugs, although effective in curing cancer, can also cause adverse late effects. The cardiotoxic effects of anthracycline chemotherapy, such as doxorubicin, and radiation can cause persistent and progressive cardiovascular damage, emphasizing a need for effective prevention and treatment to reduce or avoid cardiotoxicity. Examples of risk factors for cardiotoxicity in children include higher anthracycline cumulative dose, higher dose of radiation, younger age at diagnosis, female sex, trisomy 21 and black race. However, not all who are exposed to toxic treatments experience cardiotoxicity, suggesting the possibility of a genetic predisposition. Cardioprotective strategies under investigation include the use of dexrazoxane, which provides short- and long-term cardioprotection in children treated with doxorubicin without interfering with oncological efficacy, the use of less toxic anthracycline derivatives and nutritional supplements. Evidence-based monitoring and screening are needed to identify early signs of cardiotoxicity that have been validated as surrogates of subsequent clinically significant cardiovascular disease before the occurrence of cardiac damage, in patients who may be at higher risk.
Referred From: https://www.karger.com/Article/FullText/360238
Author(s): Long ZJ, Hu Y, Li XD, He Y, Xiao RZ, et al.
Author(s): Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, et al.
Author(s): Dalen VEC, Raphael MF, Caron HN, Kremer LC
Author(s): Swain SM, Whaley FS, Ewer MS
Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.
Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.
Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.
Author(s): Cario G, Rhein P, Mitlohner R, Zimmermann M, Bandapalli OR, et al.
Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.
Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE
Author(s): Yeh ET, Bickford CL
Author(s): Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA
Author(s): Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B
Author(s): Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F, Villa-Arranz A, et al.
Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.
Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.
Author(s): Lipshultz SE, Franco VI, Cochran TR
Author(s): Orgel E, Zung L, Ji L, Finklestein J, Feusner J, et al.
Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.
Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R
Author(s): Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, et al.
Author(s): Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, et al.
Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE
Author(s): Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, et al.
Author(s): Feuerstein GZ, Ruffolo RR
Author(s): Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, et al.
Author(s): Goldberg JM, Scully RE, Sallan SE, Lipshultz SE
Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.